(19) |
 |
|
(11) |
EP 3 587 392 A8 |
(12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
(15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
(48) |
Corrigendum issued on: |
|
27.05.2020 Bulletin 2020/22 |
(43) |
Date of publication: |
|
01.01.2020 Bulletin 2020/01 |
(22) |
Date of filing: 09.10.2015 |
|
(51) |
International Patent Classification (IPC):
|
|
(84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Validation States: |
|
MA |
(30) |
Priority: |
09.10.2014 IT FI20140230
|
(62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
15797412.2 / 3203989 |
(71) |
Applicant: Distretto Tecnologico Sicilia
Micro e Nano Sistemi S.C.A.R.L. |
|
95121 Catania (IT) |
|
(72) |
Inventors: |
|
- BLANCO, Anna Rita
95024 ACIREALE (IT)
- BONDI, Maria Luisa
90019 TRABIA (IT)
- CAVALLARO, Gennara
90122 PALERMO (IT)
- CONSOLI, Grazia Maria Letizia
95027 San Gregorio di Catania (IT)
- CRAPARO, Emanuela Fabiola
90123 PALERMO (IT)
- GIAMMONA, Gaetano
90146 PALERMO (IT)
- LICCIARDI, Mariano
90129 PALERMO (IT)
- PITARRESI, Giovanna
90123 PALERMO (IT)
- GRANATA, Giuseppe
95024 ACIREALE (IT)
- SALADINO, Patrizia
91029 SANTA NINFA (IT)
- LA MARCA, Clara
92024 CANICATTI (IT)
- DEIDDA, Irene
90125 PALERMO (IT)
- PAPASERGI, Salvatore
89029 TAURIANOVA (IT)
- GUARNERI, Patrizia
90144 PALERMO (IT)
- CUZZOCREA, Salvatore
98167 MESSINA (IT)
- ESPOSITO, Emanuela
80125 NAPOLI (IT)
- VIOLA, Santa
95047 PATERNO' (IT)
|
(74) |
Representative: Coppo, Alessandro et al |
|
Notarbartolo & Gervasi S.p.A.
Corso di Porta Vittoria, 9 20122 Milano 20122 Milano (IT) |
|
|
|
|
|
Remarks: |
|
This application was filed on 07-08-2019 as a divisional application to the application
mentioned under INID code 62. |
|
(54) |
NANOSTRUCTURED FORMULATIONS FOR THE DELIVERY OF SILIBININ AND OTHER ACTIVE INGREDIENTS
FOR TREATING OCULAR DISEASES |
(57) Formulations are described, containing silibinin or other active ingredients incorporated
in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly
mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin
copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility
of the calixarene compound is also described, capable of charging and releasing active
ingredients characterized by low water solubility, easy chemical and enzymatic degradation,
low bioavailability, either of natural origin or not, to be used in the treatment
of ocular diseases.